Fig.1
From: Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
Changes in MMD, MHD, AMD, and NRS. Line graphs are expressed as mean. Blue, green, and orange lines represent EM, CM, and ALL respectively. Please note Supplementary Fig. 1 for significant change and 95% CI. MMD, monthly migraine day; MHD, monthly headache day; AMD, monthly acute medication intake days; NRS, numerical rating scale; EM, episodic migraine; CM, chronic migraine; ALL, all patients; 1 M, 1 month; 2 M, 2 months; 3 M, 3 months